Envudeucitinib

N/A

Report date: 2025/05/23 14:38:50
NME

Base Information

Drug NameEnvudeucitinib
Drug Alias NameEnvudeucitinib HydrochlorideESK-001FTP-637
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase 2 inhibitorsProtein allosteric inhibitors
TargetsTyrosine-protein kinase 2
Therapy Area/IndicationsPlaque psoriasisAutoimmune DiseasesPsoriasis +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[31] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesHaisco Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAlumis IncKaken Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisAutoimmune DiseasesPsoriasis +[6] 
Inactive IndicationsUveitis, IntermediateUveitis, PosteriorPanuveitis

Other Information

ATC CodeN/A
Related LinksN/A